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ALAN TALEVI1,2, JULIÁN J. PRIETO1, LUIS E. BRUNO-BLANCH1, & EDUARDOA. CASTRO2,1
1Medicinal Chemistry, Department of Biological Sciences, Faculty of Exact Sciences, Universidad Nacional de La Plata
(UNLP), B1900AVV, La Plata, Buenos Aires, Argentina, and 2Instituto de Investigaciones Fisicoquı́micas Teóricas y Aplicadas
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Abstract
A similarity-based algorithm based on a previously developed model is applied in the classification of two sets of
anticonvulsant and non-anticonvulsant drugs. Each set is composed of a) anticonvulsant compounds that have shown
moderate to high activity in the Maximal Electroshock Seizure (MES) test and b) drugs with other biological activities or poor
activity in the MES test. The results from the analysis of variance (ANOVA) indicate that the proposed algorithm is able to
differentiate anticonvulsant from non-anticonvulsant drugs. The proposed model may then be useful in the identification of
new anticonvulsant agents through virtual screening of large virtual libraries of chemical structures.
Keywords: Anticonvulsant, molecular topology, atom pairs, MES test, chemical substructure
Introduction
Despite the continuous development of 3D and 4D
QSAR methodologies, 2D-descriptors still remain
among the most widely used descriptors in pharma-
ceutical research today [1–5]. This is, in part, because
3D descriptors depend on the conformation used to
represent the molecule, which not necessarily corres-
ponds to the conformation responsible for activity,
which may be sometimes difficult to define [6–8].
Furthermore, although their physicochemical meaning
is not always clear, 2D descriptors do not depend on
the molecule conformation, have a low computational
expense and can be easily calculated for all the existing,
new, and in-development chemical structures [6,9].
There are, essentially, two major types of molecular
descriptors [10]. The first of them has been defined as
“holistic”. Descriptors of this class are numbers that
usually represent some important physical property of
the whole molecule. These descriptors are either
empirical or theoretical. Examples that could be
mentioned among many others are: octanol-water
partition coefficient, [11] Kier Shape Index and [12]
the shape indices of Hopfinger [13] [14].
The other descriptor category consists of the so-
called chemical substructures [1,10]. They could be
interpreted as subgraphs of the graph that is associated
to a molecular structure. These subgraphs are labeled
or colored in a way that reflects information such as:
atomic species, bond types and connectivity of two or
more atoms from the structure. Some examples of
descriptors in this category are atom pairs (AP),
[1,14,15] topological torsions (TT), [1,10] atom
sequences (AS) and the Index of Electrotopological
state [15,16]. Chemical substructures are particularly
useful in the generation of similarity algorithms
for retrieval systems and compound classification
[17,18], which are commonly used in virtual screening
of large chemical structure libraries. One of the main
advantages of similarity algorithms in pharmaceutical
discovery is that little information is needed to
formulate a reasonable query; similarity methods can
be applied at the beginning of a drug discovery project
when there is little or no information available on the
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molecular target [6]. We present a similarity-based
algorithm generated on the basis of the one previously
developed by Bagchi and Maiti [19]. We have applied
the proposed model in the classification of two sets of
molecules composed by both anticonvulsant and non-
anticonvulsant drugs.
Motivation
Epilepsy is one of the most common neurological
disorders that affect human condition. It is character-
ized by recurrent seizure attacks that range from a
brief lapse of attention to severe, frequent convulsions
due to synchronous neuronal firing. About 50 million
people in the world suffer from epilepsy, especially in
childhood, adolescence and old age [20,21]. Available
treatment fails to control epilepsy in up to 30% of
the patients. In non-developed countries about
three-fourths of patients do not receive the treatment
they need [21]. Moreover, even the new generation
of antiepileptic drugs (AEDs) causes important side
effects, including headache, drowsiness, diplopia,
ataxia, dizziness, nausea, allergies, blood dyscrasias
and hepatotoxicity [22]. Thus safer, more efficient,
less toxic new AEDs are urgently needed.
Atom pair definition
In 1985 Carhart et al. [15] defined an atom pair as a
substructure composed of two non-hydrogen atoms
and an interatomic separation.
ðatom1descriptionÞðseparationÞðatom2descriptionÞ
“Separation” is measured as the number of atoms
in the shortest bond-by-bond path that contains
atoms 1 and 2. Since the “topological distance” is
defined as the number of edges, by the shortest bond-
by-bond path, between two atoms [9], Carhart
separation corresponds to the topological distance
plus one. “Description” of each atom informs its
chemical type, the number of non-hydrogen atoms
attached to it and the number of bonding p electrons it
bears. An asterisk or dot following an atom symbol
represents the presence of a bonding p electron. Xn
following an atom symbol indicates the presence of n
non-hydrogen neighboring atoms.
For any given chemical structure denoted by j, the
total number of APs d(j) that can be derived from it is





n being the number of non-hydrogen atoms present in
the compound j.
Pharmacophore definition
Pharmacophore models are hypotheses on the 3D
arrangement of structural properties, such as hydrogen
bond donor and acceptor properties, hydrophobic
groups and aromatic rings of compounds that bind to a
biological target [23,24].
Our group has identified a pharmacophore related
to anticonvulsant activity mediated by sodium
channels blockade [25,26] through fitting in SYBYL
6.6 [27]. A model of the identified pharmacophore
can be seen in Figure 1.
In the present work we have used information
derived from this identified pharmacophore to
generate a new mathematical model, specific for the
search for potential new anticonvulsants, on the basis
of the one from Bagchi and Maiti [19].
On similarity determination
There are two major classes of similarity coefficients:
association and distance coefficients. The essential
difference between them is that the latter considers the
common absence of certain structural features as the
evidence of similarity between two chemical structures,
whereas the former does not. Mentionable examples of
association coefficients are Tanimoto, Dice and Cosine
coefficients. Examples of distance coefficients are
Hamming and Euclidean distances [15,18].
The work from Chen et al. [15] indicates that the
Tanimoto coefficient shows better performance than
the Euclidean distance in 2D fragment-based similarity
searching. Based on this information, we decided to use
the Tanimoto coefficient as the similarity measure in the
proposed model. We have tested the model with the
Tanimoto coefficient in both its binary (Equation 2)





where a is the number of types of fragments in
compound A; b is the number of types of fragments in
compound B and c is the number of types of fragments














Figure 1. Identified pharmacophore for anticonvulsant drugs
acting through sodium channel blockade mechanism.
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where nai is the number of times that the ith AP appears
in the AP set derived from compound A and nbi is the
number of times that the ith AP appears in the AP set
derived from compound B.
Materials and methods
Construction of the compounds sets
Two sets of compounds were constructed. Set A
includes 12 compounds with high and moderate
activity in the MES test (ED50 below 100 mg/kg, in
mice) as well as 11 drugs with other therapeutic uses,
extracted from Merck Index 13th [28]: aspirin
(analgesic), abikoviromycin (antibiotic), oxantel (anti-
parasitary), lindane (pediculicide), acipimox (anti-
hyperlipoproteinemic), acecarbromal (hypnotic),
etanidazole (antineoplasic), ABT-594 (analgesic),
bergapten (antipsoriatic), methizasone (antiviral)
and methocarbamol (muscle relaxant). Two anti-
convulsants with poor activity in the MES test were
also included (ethosuximide and TV-1901). The
anticonvulsant agents included in Set A (Figure 2)
are structurally diverse. Carbamazepine was chosen
as the reference drug of this set, this is, the structure
to which all the other molecules in the set will be
compared through the proposed algorithm. Carba-
mazepine’s measured activity in the MES test is the
highest among set A (ED50 ¼ 37mmol/kg ip) [25].
Set B (Figure 3) is defined by 26 compounds.
Besides the non-anticonvulsant drugs already used in
set A, it includes 13 anticonvulsants: one benzoqui-
noxaline derivative (NBQX), nine benzodiazepine and
tetrahydroisoquinoline derivatives selected from a set
of drugs tested in the MES test [29,30], as well as
Figure 2. Structures of the compounds that compose set A. Anticonvulsant compounds are shown in black, while compounds with other
therapeutic uses are presented in grey. Carbamazepine was chosen as the reference compound in this set.
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carbamazepine and valpramide. THIQ – 10c, the
compound with the highest measured activity in the
MES test among set B (ED50 ¼ 5.17mmol/kg) was
chosen as reference drug. Note that the anti-
convulsants in set B are structurally less hetero-
geneous than those in set A.
The structures of each set with high and moderate
anticonvulsant activity in the MES test will be referred
to as active compounds from now on. This category
is presented in black in Figures 2 and 3. On the other
hand, the compounds with other therapeutic uses or
poor anticonvulsant activity in the MES test are
presented in grey and will be referred to as inactive
compounds.
Construction of the new model
We propose the following model:










Figure 3. Schematic representation of compounds that define set B. Anticonvulsant compounds are shown in black, while compounds with
other therapeutic uses are presented in grey. It can be appreciated that many of the anticonvulsants of this set are structurally closely-related.
THIQ-10c was chosen as the reference compound in Set B.
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A is a measure of the expected relative activity to a
reference drug; this is chosen as the most active
structure of the working set (carbamazepine for set A
and THIQ-10c for set B). S is the binary form of the
Tanimoto similarity coefficient. ni represents the
number of ith AP in the reference drug; Dni stands
for the difference of ith AP between the reference drug
and the tested drug; li is the separation in the ith AP
and a is the separation in the longest AP that can be
derived from the identified pharmacophore (or, in other
words, a represents the maximal topological distance in
the pharmacophore plus one). For the term between
brackets we consider only those types of AP that
contain heteroatoms, based on the common knowledge
that bioactive compounds tend to present heteroatoms
and heterocycles and that functional groups involved in
non-covalent short-distance interactions are essential
for the binding of the drug to its site of action. b and c
are constants which moderate the influence over the
predicted relative activity of the similarity coefficient
and the second term between brackets.
The value of each one of the terms in the sum
between brackets can be interpreted as the contribution
of the ith type of AP to the activity of the structure.
Whether these terms are positive or negative (adding to
or reducing the relative activity of the molecule that
is being compared) is defined by the Dni factor, which
is the only one among the factors involved in the
model that can take values either greater or smaller
than zero. Since the reference drug of each set is
chosen as the most active structure in it, the types of AP
that are present in the reference drugs can be thought
of as desired features involved in the interaction of
the molecule and its site of action. This was one
of the fundamental hypotheses in the development of
our model. Therefore, if the number of APs of the ith
type is greater in the reference drug than in the tested
compound, then the tested molecule is lacking a
desired feature and the fraction of the activity that can
be explained, through that particular element will be
smaller in the tested compound than in the reference
one. If the number of ith type elements is greater in the
tested compound than in the reference drug, then the
tested compound has more of a desired characteristic
and a greater probability of this feature being expressed
at the time of interacting with the site of action.
However, are all the types of atom pairs equally
significant to the activity of a particular structure?
Since the reference is the drug with the highest
activity among the available structures, we believe
that the more times a particular type of AP appears
in the reference structure, the more important is the
contribution of that type of AP to the activity. Thus,
our model includes the factor ni in the numerator of
the second term between brackets. We also believe
that, having indentified a specific pharmacophore, we
should give more attention to the types of AP that
somehow accomplish the characteristics of the
pharmacophoric pattern. The topological distances
are one of the features of the pharmacophore that can
be considered. We decided to give prominence to
those types of AP that include heteroatoms and a
separation of six, since six is the maximum number of
atoms comprised in the possible AP derived from the
identified pharmacophore for anticonvulsant drugs
with activity in the MES test.
Although the pharmacophore itself could be used as
a 3D-search query in virtual screening for new
anticonvulsant agents through compound databases,
this requires the previous generation of reasonable,
low-energy conformers of the molecules in the
database to be screened. Our model presents the
advantage that, since only topological, 2D-features of
the pharmacophore are considered, the results of the
query do not depend on the conformation of the
molecules from the database being screened.
Application of the models
The AP set derived of each of the compounds
considered for this study was generated. Table I shows
the complete sets of AP for carbamazepine and
THIQ-10c, the reference compounds of set A and
set B, in that order. Once we had knowledge of all the
AP sets the similarity coefficients of Tanimoto were
calculated as specified in Equations (2) and (3); the
values of these coefficients for each structure are
shown in Table III. In order to determine the common
heteroatom APs, the APs of each structure was
compared with the APs of the corresponding reference
drug. Different values for b and c were tested for each
set of compounds. b was given values of 0.5, 0.75 and
1. c was given values of 50 and 75. As an example,
Table II shows the types of heteroatom AP common to
carbamazepine and phenytoin, and the occurrence of
each type in each one of these structures. The
calculated value for the negative term between
brackets in the proposed model is also shown; c was
chosen as equal to 75 for the example presented in
Table II. Once we calculated the value of A for the
different forms of model (4), analysis of variance
(ANOVA) was performed in order to determine if the
proposed model could be used to classify antic-
onvulsant and non-anticonvulsant agents. In other
words, it was checked if there was a statistically
significant difference between the mean values of A
for the active and the inactive categories of both set
A and B. It was also verified if that difference was
either similar or higher, in terms of statistical
significance, than the difference between the mean
values of the Tanimoto coefficients for both groups
(active and inactive) and both sets.
Scatter plots of log ED50 in the MES test versus A
(obtained through Equation (5) using Tanimoto
coefficient in its algebraic form) were drawn in order
to determine if there was correlation between the
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Table I. AP sets derived from carbamazepine and THIQ-10c structures.
Carbamazepine THIQ-10c
Count Atom pair Count Atom pair Count Atom pair
7 C*X2-2-C*X2 2 C*X2-2-C*X2 2 CX1-5-C*X2
2 C*X3-2-C*X3 8 C*X2-2-C*X3 4 CX1-5-C*X3
6 C*X2-2-C*X3 2 C*X2-3-BrX1 1 CX1-5-CX2
1 C*X3-2-NX1 2 C*X2-3-C*X2 2 CX1-5-OX2
3 C*X3-2-NX3 8 C*X2-3-C*X3 3 CX1-6-C*X2
1 C*X3-2-O*X1 2 C*X2-3-OX2 3 CX1-6-C*X3
6 C*X2-3-C*X2 2 C*X2-4-BrX1 1 CX1-6-CX1
11 C*X2-3-C*X3 3 C*X2-4-C*X2 1 CX1-6-CX2
2 C*X2-3-NX3 3 C*X2-4-C*X3 1 CX1-6-CX3
8 C*X2-4-C*X2 3 C*X2-4-NX3 3 CX1-7-C*X2
10 C*X2-4-C*X3 2 C*X2-4-OX2 1 CX1-7-C*X3
6 C*X2-4-NX3 2 C*X2-5-C*X2 2 CX1-7-CX2
7 C*X2-5-C*X2 8 C*X2-5-C*X3 1 CX1-7-CX3
14 C*X2-5-C*X3 3 C*X2-5-NX3 1 CX1-7-NX3
2 C*X2-5-NX1 4 C*X2-6-C*X2 2 CX1-8-C*X2
2 C*X2-5-NX3 7 C*X2-6-C*X3 5 CX1-8-C*X3
2 C*X2-5-O*X1 3 C*X2-6-O*X1 1 CX1-8-CX2
7 C*X2-6-C*X2 2 C*X2-7-C*X2 1 CX1-8-NX3
8 C*X2-6-C*X3 4 C*X2-7-C*X3 1 CX1-8-OX2
6 C*X2-6-NX3 3 C*X2-7-O*X1 1 CX1-9-BrX1
6 C*X2-6-O*X1 2 C*X2-7-OX2 4 CX1-9-C*X2
7 C*X2-7-C*X2 1 C*X2-8-BrX1 1 CX1-9-C*X3
2 C*X2-7-NX1 3 C*X2-8-C*X3 1 CX1-9-CX1
2 C*X2-7-O*X1 4 C*X2-8-OX2 1 CX1-9-O*X1
3 C*X2-8-C*X2 1 C*X2-9-BrX1 1 CX1-9-OX2
4 C*X3-3-C*X3 2 C*X2-9-OX2 1 CX2-2-C*X3
2 C*X3-3-NX3 1 C*X3-10-BrX1 1 CX2-2-CX2
5 C*X3-4-C*X3 1 C*X3-10-OX2 1 CX2-2-NX3
2 C*X3-4-NX1 1 C*X3-2-BrX1 1 CX2-3-C*X2
2 C*X3-4-OX1 2 C*X3-2-C*X3 3 CX2-3-C*X3
2 C*X3-5-NX1 1 C*X3-2-NX3 1 CX2-3-CX3
2 C*X3-5-O*X1 1 C*X3-2-O*X1 1 CX2-3-NX3
1 NX1-3-O*X1 2 C*X3-2-OX2 2 CX2-4-C*X2
1 NX3-3-NX1 3 C*X3-3-C*X3 4 CX2-4-C*X3
1 NX3-3-O*X1 2 C*X3-3-NX3 1 CX2-4-CX3
7 C*X2-2-C*X2 2 C*X3-3-OX2 1 CX2-4-O*X1
2 C*X3-2-C*X3 6 C*X3-4-C*X3 3 CX2-5-C*X2
6 C*X2-2-C*X3 1 C*X3-4-NX3 3 CX2-5-C*X3
1 C*X3-2-NX1 2 C*X3-4-OX2 1 CX2-5-O*X1
3 C*X3-2-NX3 1 C*X3-5-BrX1 1 CX2-5-OX2
1 C*X3-2-O*X1 2 C*X3-5-C*X3 4 CX2-6-C*X2
6 C*X2-3-C*X2 1 C*X3-5-NX3 1 CX2-6-C*X3
11 C*X2-3-C*X3 2 C*X3-5-O*X1 2 CX2-6-OX2
2 C*X2-3-NX3 2 C*X3-5-OX2 2 CX2-7-C*X2
8 C*X2-4-C*X2 3 C*X3-6-C*X3 1 CX2-7-C*X3
10 C*X2-4-C*X3 2 C*X3-6-NX3 1 CX2-7-OX2
6 C*X2-4-NX3 1 C*X3-6-O*X1 1 CX2-8-BrX1
7 C*X2-5-C*X2 1 C*X3-6-OX2 1 CX2-9-BrX1
14 C*X2-5-C*X3 1 C*X3-7-BrX1 2 CX3-2-C*X3
2 C*X2-5-NX1 1 C*X3-7-C*X2 1 CX3-2-NX3
2 C*X2-5-NX3 2 C*X3-7-C*X3 3 CX3-3-C*X2
2 C*X2-5-O*X1 1 C*X3-7-O*X1 2 CX3-3-C*X3
7 C*X2-6-C*X2 2 C*X3-7-OX2 3 CX3-4-C*X2
8 C*X2-6-C*X3 2 C*X3-8-BrX1 1 CX3-4-C*X3
6 C*X2-6-NX3 1 C*X3-8-C*X3 1 CX3-4-O*X1
6 C*X2-6-O*X1 2 C*X3-8-O*X1 2 CX3-5-C*X3
7 C*X2-7-C*X2 1 C*X3-8-OX2 1 CX3-5-OX2
2 C*X2-7-NX1 1 C*X3-9-BrX1 1 CX3-6-BrX1
2 C*X2-7-O*X1 1 C*X3-9-C*X3 1 CX3-6-OX2
3 C*X2-8-C*X2 1 C*X3-9-OX2 1 CX3-7-C*X3
4 C*X3-3-C*X3 2 CX1-10-C*X2 1 CX3-8-C*X3
2 C*X3-3-NX3 1 CX1-10-C*X3 1 NX3-3-O*X1
5 C*X3-4-C*X3 1 CX1-10-CX1 1 NX3-6-OX2
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Table I – continued
Carbamazepine THIQ-10c
Count Atom pair Count Atom pair Count Atom pair
2 C*X3-4-NX1 1 CX1-10-O*X1 1 NX3-7-BrX1
2 C*X3-4-OX1 1 CX1-11-BrX1 1 NX3-7-OX2
2 C*X3-5-NX1 1 CX1-11-C*X3 1 O*X1-9-BrX1
2 C*X3-5-O*X1 1 CX1-12-BrX1 1 OX2-10-BrX1
1 NX1-3-O*X1 1 CX1-2-C*X3 1 OX2-11-BrX1
1 NX3-3-NX1 2 CX1-2-OX2 1 OX2-4-OX2
1 NX3-3-O*X1 2 CX1-3-C*X3 1 OX2-8-O*X1
7 C*X2-2-C*X2 1 CX1-3-NX3 1 OX2-9-O*X1
2 C*X3-2-C*X3 1 CX1-3-O*X1 1 CX1-4-CX2
6 C*X2-2-C*X3 2 CX1-4-C*X2 1 CX1-4-CX3
1 C*X3-2-NX1 2 CX1-4-C*X3
Table II. Heteroatom APs common to carbamazepine and phenytoin, and the value of the negative term between brackets in expression (3)
for each type of AP.





C*X3-2-O*X1 1 2 20.267
C*X2-5-O*X1 2 4 22.667
C*X2-6-O*X1 6 7 28.000
C*X2-7-O*X1 2 6 25.333
C*X3-4-OX1 2 4 21.773
C*X3-5-O*X1 2 2 0.000
Table III. Value of the Tanimoto coefficient (in its binary and algebraic form) for every compound tested. Compounds which compose set A
were compared to carbamazepine. Compounds which composed set B were compared to THIQ-10c. Inactive compounds are presented in
grey.
Compound Binary form of Tanimoto coefficient Algebraic form of Tanimoto coefficient
S ADCI 0.34 0.72
E Cannabidiol 0.08 0.12
T Felbamate 0.15 0.14





















S Carbamazepine 0.14 0.40
E CFM11 0.35 0.58
T CFM11S 0.13 0.55
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Table III – continued
Compound Binary form of Tanimoto coefficient Algebraic form of Tanimoto coefficient
GYKI 57655 0.42 0.64
















Table IV. Value of A for the compounds of Set A and B, obtained with the form of the proposed model specified in expression (5).
Compound A (with binary form of S) A (with algebraic form of S)
S ADCI 0.34 0.60
E Cannabidiol 0.15 0.22
T Felbamate 0.25 0.24





















S Carbamazepine 0.25 0.55
E CFM11 0.42 0.61
T CFM11S 0.22 0.66




GYKI 57655 0.55 0.75
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activity predicted with our model and the experimen-
tal activity measured in the MES test, for both sets A
and B. For comparison purposes, the scatter plots of
log ED50 versus the Tanimoto coefficient in its
algebraic form were also drawn.
The model was finally validated with a set of ten
compounds with bioactivities different from anti-
convulsant activity (Figure 6).
Results and discussion
Table IV shows the values of A for one of the forms of
the proposed model that showed good performance in
both sets A and B, both with the binary and algebraic
forms of the Tanimoto coefficient:










Table V shows the results from the ANOVA test for
the different forms of the proposed model that were
evaluated and for the bare Tanimoto coefficient (in its
binary and algebraic form). We present the value of
the F Statistical (which represents the ratio between
the variance between-groups and the variance within-
group) and the p-value (which indicates the level of
significance of the difference between the mean values
of the considered categories). It can be observed that
Table IV – continued














Table V. Values of the statisticals F and p for the different forms of the proposed model that were tested. Each form of the model corresponds
to different values of b and c in (3). Values of F and p are also presented for the Tanimoto coefficient. The first set of data corresponds to the
models which incorporate the binary form of the Tanimoto coefficient; the second set of data, to the models which incorporate the algebraic
form of the Tanimoto coefficient. Note that difference between the mean values of the algorithm for both considered categories is statistically
more significant when the algebraic form of Tanimoto coefficient is used.
S=Binary form of Tanimoto coefficient
c=50 c=75
Tanimoto Coefficient S (binary form) b=0.50 b=0.75 b=1.00 b=0.50 b=0.75 b=1.00
SETA F ¼ 5.93 F ¼ 3.81 F ¼ 4.23 F ¼ 4.11 F ¼ 5.44 F ¼ 5.39 F ¼ 4.99
p ¼ .023 p ¼ .063 p ¼ .051 p ¼ .055 P ¼ .030 p ¼ .030 p ¼ .036
SET B F ¼ 9.90 F ¼ 13.58 F ¼ 13.22 F ¼ 12.25 F ¼ 12.54 F ¼ 12.12 F ¼ 11.49
p ¼ .005 p ¼ .001 p ¼ .001 p ¼ .002 P ¼ .002 p ¼ .002 p ¼ .0025
S ¼ Algebraic form of Tanimoto coefficient
c ¼ 50 c ¼ 75
Tanimoto Coefficient (algebraic form) b ¼ 0.50 b ¼ 0.75 b ¼ 1.00 b ¼ 0.50 b ¼ 0.75 b ¼ 1.00
SETA F ¼ 5.67 F ¼ 4.13 F ¼ 4.51 F ¼ 4.44 F ¼ 5.16 F ¼ 5.30 F ¼ 5.06
p ¼ .026 p ¼ .054 p ¼ .045 p ¼ .047 P ¼ .033 p ¼ .031 p ¼ .035
SET F ¼ 38.19 F ¼ 34.66 F ¼ 42.35 F ¼ 46.33 F ¼ 34.24 F ¼ 41.04 F ¼ 44.59
p , .0000 p , .0000 p , .0000 p , .0000 P , .0000 P , .0000 p , .0000
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the performance of various forms of the proposed
model in the classification of compounds from set A is
similar to that of the Tanimoto coefficients, while in
the case of set B the difference between the mean value
of A is more significant than the difference between
the mean values of the Tanimoto coefficients for
each considered category. Taking into account that
most of the anticonvulsants which compose set B are
structurally related to THIQ 10c, results seem to
indicate that the proposed model is effective in the
identification of anticonvulsant compounds whose
structure is close-related to the structure of the
compound chosen as a reference (Figure 4). Figure 4
also shows that the difference between the categories is
statistically much more significant when using in the
model the Tanimoto coefficient in its algebraic form.
This reflects the fact that the differences between the
mean values of the Tanimoto coefficient for the active
and inactive categories is also much greater for Set B
for the algebraic than for the binary form.
Figure 5 shows that there are strong correlations
between the measured log ED50 in the MES test and
Figure 4. Results from ANOVA test on the values of A calculated from expression (5) for set B, for both considered categories. The upper
graph corresponds to the model that incorporates the binary form of the Tanimoto coefficient, while the lower corresponds to the model that
incorporates the algebraic form.
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the values of A. The correlation coefficients r for both
sets A and B (0.8149 and 0.9055, in that order) are
higher than those obtained when plotting log ED50
versus the algebraic form of the Tanimoto coefficient
(0.7962 and 0.8568).
Table VI shows the results from the validation of
model (5) (using the algebraic form of the Tanimoto
coefficient and taking THIQ10c as the reference
compound). Nine of the ten inactive compounds
have low A values that fall inside or below the 0.95
Figure 5. On the left, scatter plots of log10 ED50 versus A (calculated through expression 5) for the anticonvulsant compounds of both sets A
and B. On the right, log10 ED50 versus algebraic form of the Tanimoto coefficient.
Figure 6. Structures of the 10 non-anticonvulsant drugs used for validation purposes.
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confidence interval for the inactive category (see
Figure 4). The A value of the remaining compound
(lefetamine), although higher, falls below the 0.95
confidence interval for the active category.
Conclusions
A new similarity-based algorithm for the classification
of anticonvulsant and non-anticonvulsant drugs is
introduced and applied in the classification of two
sets of compounds, both composed of anticonvulsant
and non-anticonvulsant agents in the MES test. The
ANOVA test showed statistically significant differ-
ences between the mean values of the algorithm for
each considered category. Results indicate that the
proposed algorithm performs better in the identifi-
cation of anticonvulsant compounds structurally
close-related to the reference compound chosen for
the query. The algorithm could be applied in the
search for new anticonvulsant agents through virtual
screening.
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